Mostrar el registro sencillo del ítem

dc.contributor.authorZazo, Hinojal
dc.contributor.authorColino, Clara I
dc.contributor.authorLanao, José M 
dc.date.accessioned2025-01-20T11:03:31Z
dc.date.available2025-01-20T11:03:31Z
dc.date.issued2016-02-28
dc.identifier.issn0168-3659
dc.identifier.urihttp://hdl.handle.net/10366/162004
dc.description.abstractFor decades infections have been treated easily with drugs. However, in the 21st century, they may become lethal again owing to the development of antimicrobial resistance. Pathogens can become resistant by means of different mechanisms, such as increasing the time they spend in the intracellular environment, where drugs are unable to reach therapeutic levels. Moreover, drugs are also subject to certain problems that decrease their efficacy. This requires the use of high doses, and frequent administrations must be implemented, causing adverse side effects or toxicity. The use of nanoparticle systems can help to overcome such problems and increase drug efficacy. Accordingly, there is considerable current interest in their use as antimicrobial agents against different pathogens like bacteria, virus, fungi or parasites, multidrug-resistant strains and biofilms; as targeting vectors towards specific tissues; as vaccines and as theranostic systems. This review begins with an overview of the different types and characteristics of nanoparticles used to deliver drugs to the target, followed by a review of current research and clinical trials addressing the use of nanoparticles within the field of infectious diseases.es_ES
dc.language.isoenges_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAmphotericin B (PubChem CID: 5280965); Antimicrobial; Chloroquine (PubChem CID: 2719); Drug delivery; Fluconazole (PubChem CID: 3365); Gentamicin (PubChem CID: 3467); Infections; Nanoparticles; Penicillin (PubChem CID: 5904); Rifampicin (PubChem CID: 5381226); Saquinavir (PubChem CID: 60934); Streptomycin (PubChem CID: 5999); Vancomycin (PubChem CID: 14969); Zidovudine (PubChem CID: 35370).es_ES
dc.subject.meshNanoparticles *
dc.subject.meshAnimals *
dc.subject.meshAnti-Infective Agents *
dc.subject.meshHumans *
dc.subject.meshDrug Delivery Systems *
dc.titleCurrent applications of nanoparticles in infectious diseases.es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.identifier.doi10.1016/j.jconrel.2016.01.008
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.pmid26772877
dc.identifier.essn1873-4995
dc.journal.titleJournal of controlled release : official journal of the Controlled Release Societyes_ES
dc.volume.number224es_ES
dc.page.initial86es_ES
dc.page.final102es_ES
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES
dc.subject.decsnanopartículas *
dc.subject.decsanimales *
dc.subject.decssistemas de liberación de medicamentos *
dc.subject.decshumanos *
dc.subject.decsantiinfecciosos *


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 Internacional